Zacks Research Issues Pessimistic Outlook for PBYI Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities researchers at Zacks Research lowered their FY2024 EPS estimates for shares of Puma Biotechnology in a report issued on Thursday, January 9th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.31 per share for the year, down from their prior estimate of $0.32. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q1 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.13 EPS, Q1 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.25 EPS.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Puma Biotechnology Stock Down 6.9 %

Puma Biotechnology stock opened at $3.08 on Monday. The business’s 50-day simple moving average is $3.06 and its two-hundred day simple moving average is $2.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The company has a market cap of $151.19 million, a PE ratio of 6.42 and a beta of 1.10. Puma Biotechnology has a fifty-two week low of $2.22 and a fifty-two week high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.10. The firm had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same period in the prior year, the firm earned $0.12 EPS.

Hedge Funds Weigh In On Puma Biotechnology

A number of hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Puma Biotechnology in the 3rd quarter valued at $34,000. Franklin Resources Inc. purchased a new stake in shares of Puma Biotechnology during the third quarter worth $41,000. Victory Capital Management Inc. acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $54,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Puma Biotechnology in the third quarter worth about $44,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Puma Biotechnology during the second quarter worth about $58,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insider Buying and Selling at Puma Biotechnology

In other Puma Biotechnology news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now owns 108,951 shares in the company, valued at approximately $343,195.65. This represents a 7.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. The trade was a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 23.70% of the stock is owned by corporate insiders.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.